Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1956 1
1958 1
1961 1
1962 2
1964 6
1965 9
1966 5
1967 8
1968 2
1969 3
1970 5
1971 4
1972 7
1973 5
1974 5
1975 10
1976 4
1977 6
1978 9
1979 15
1980 12
1981 5
1982 13
1983 25
1984 17
1985 29
1986 20
1987 15
1988 29
1989 34
1990 31
1991 29
1992 35
1993 45
1994 41
1995 36
1996 38
1997 44
1998 28
1999 39
2000 68
2001 49
2002 63
2003 45
2004 64
2005 58
2006 60
2007 69
2008 84
2009 81
2010 80
2011 88
2012 102
2013 129
2014 131
2015 120
2016 100
2017 97
2018 104
2019 95
2020 116
2021 104
2022 108
2023 105
2024 41

Text availability

Article attribute

Article type

Publication date

Search Results

2,564 results

Results by year

Filters applied: . Clear all
Page 1
Reply to Letter to Editor Regarding Article "C-Reactive Protein/Albumin Ratio is an Independent Risk Factor for Recurrence and Survival Following Curative Resection of Stage I-III Colorectal Cancer in Older Patients".
Bekki T, Shimomura M, Yano T, Akabane S, Hattori M, Mochizuki T, Ono K, Matsubara K, Imaoka K, Ishikawa S, Watanabe A, Sato S, Ohdan H. Bekki T, et al. Among authors: hattori m. Ann Surg Oncol. 2024 Apr 28. doi: 10.1245/s10434-024-15300-1. Online ahead of print. Ann Surg Oncol. 2024. PMID: 38679678 No abstract available.
Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study.
Yoshinami T, Nagai SE, Hattori M, Okamura T, Watanabe K, Nakayama T, Masuda H, Tsuneizumi M, Takabatake D, Harao M, Yoshino H, Mori N, Yasojima H, Oshiro C, Iwase M, Yamaguchi M, Sangai T, Kosaka N, Tajima K, Masuda N. Yoshinami T, et al. Among authors: hattori m. Breast Cancer. 2024 Apr 20. doi: 10.1007/s12282-024-01575-5. Online ahead of print. Breast Cancer. 2024. PMID: 38642245
Genomic Landscape of Circulating Tumor DNA in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Treated With Abemaciclib: Data From the SCRUM-Japan Cancer Genome Screening Project.
Hattori M, Serelli-Lee V, Naito Y, Yamanaka T, Yasojima H, Nakamura R, Fujisawa T, Imai M, Nakamura Y, Bando H, Kawaguchi T, Yoshino T, Iwata H. Hattori M, et al. JCO Precis Oncol. 2024 Apr;8:e2300647. doi: 10.1200/PO.23.00647. JCO Precis Oncol. 2024. PMID: 38635933
The Second International Consensus Guidelines on the Management of BK Polyomavirus in Kidney Transplantation.
Kotton CN, Kamar N, Wojciechowski D, Eder M, Hopfer H, Randhawa P, Sester M, Comoli P, Tedesco Silva H, Knoll G, Brennan DC, Trofe-Clark J, Pape L, Axelrod D, Kiberd B, Wong G, Hirsch HH; Transplantation Society International BK Polyomavirus Consensus Group. Kotton CN, et al. Transplantation. 2024 Apr 12. doi: 10.1097/TP.0000000000004976. Online ahead of print. Transplantation. 2024. PMID: 38605438
2,564 results